Derivatives of human complement component C3 for therapeutic complement depletion: A novel class of therapeutic agents

Advances in Experimental Medicine and Biology

Volumn 632, Issue , 2008, Pages 293-307

  Fritzinger, David C ^a   Hew, Brian E ^a   Lee, June Q ^a   Newhouse, James ^b   Alam, Maqsudul ^c   Ciallella, John R ^d   Bowers, Mallory ^d   Gorsuch, William B ^e   Guikema, Benjamin J ^e   Stahl, Gregory L ^e   Vogel, Carl Wilhelm ^e  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b Maui High Performance Computing Center   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d Melior Discovery Inc   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; HC3 1496; HYBRID PROTEIN; SNAKE VENOM; UNCLASSIFIED DRUG; COBROTOXIN; COMPLEMENT;

ALPHA CHAIN; ARTHRITIS; BETA CHAIN; CARBOXY TERMINAL SEQUENCE; COMPLEMENT INHIBITION; DISEASE MODEL; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; REPERFUSION INJURY; REVIEW; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; MOUSE; PROTEIN ENGINEERING; PROTEIN SECONDARY STRUCTURE;

MUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; COBRA VENOMS; COMPLEMENT C3; COMPLEMENT SYSTEM PROTEINS; HUMANS; MICE; MYOCARDIAL REPERFUSION INJURY; PROTEIN ENGINEERING; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT FUSION PROTEINS;

EID: 58149354314     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-78952-1_21     Document Type: Review

References (55)

1. Andrä, J., Halter, R., Kock, M. A., Niemann, H., Vogel, C.-W., and Paul, D. (2002). Generation and characterization of transgenic mice expressing cobra venom factor. Mol Immunol 39, 357-395
2. Brand, D. D., Myers, L. K., Terato, K., Whittington, K. B., Stuart, J. M., Kang, A. H., and Rosloniec, E. F. (1994). Characterization of the T cell determinants in the induction of autoimmune arthritis by bovine alpha 1(II)-CB11 in H-2q mice. J Immunol 152, 3088-3097
3. Carroll, M. C. (2004). The complement system in B cell regulation. Mol Immunol 41, 141-146
4. Cochrane, C. G., Müller-Eberhard, H. J., and Aikin, B. S. (1970). Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol 105, 55-69
5. Costa, C., Zhao, L., Burton, W. V., Rosas, C., Bondioli, K. R., Williams, B. L., Hoagland, T. A., Dalmasso, A. P., and Fodor, W. L. (2002). Transgenic pigs designed to express human CD59 and H-transferase to avoid humoral xenograft rejection. Xenotransplantation 9, 45-57
6. de Bruijn, M. H. and Fey, G. H. (1985). Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci U S A 82, 708-712
7. Fodor, W. L., Rollins, S. A., Guilmette, E. R., Setter, E., and Squinto, S. P. (1995). A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex. J Immunol 155, 4135-4138
8. Fritzinger, D. C., Petrella, E. C., Connelly, M. B., Bredehorst, R., and Vogel, C.-W. (1992). Primary structure of cobra complement component C3. J Immunol 149, 3554-3562
9. Fritzinger, D. C., Bredehorst, R., and Vogel, C.-W. (1994). Molecular cloning and derived primary structure of cobra venom factor. Proc Natl Acad Sci U S A 91, 12775-12779
10. Fritzinger, D. C., Hew, B. E., Thorne, M., and Vogel, C.-W. (2004). Functional characterization of cobra venom factor/cobra C3 hybrid proteins. Mol Immunol 41, 230
11. Fritzinger, D. C., Hew, B. E., Pangburn, M. K., and Vogel, C.-W. (2005). Generation of human C3 derivatives with CVF-like function for therapeutic complement depletion. FASEB J 19, A324
12. Fritzinger, D. C., Hew, B. E., Pangburn, M. K., Janssen, B. J. C., Gros, P., and Vogel, C.-W. (2006). Human C3/cobra venom factor hybrid proteins with potential therapeutic applications. Mol Immunol 43, 141-142
13. Fritzinger, D. C., Hew, B. E., Lee, J. Q., and Vogel, C.-W. (2007). Human C3/cobra venom factor hybrid proteins for therapeutic complement depletion: in vivo activity and fine mapping of important domains. Mol Immunol 44, 3945
14. Fritzinger, D. C., Hew, B. E., Thorne, M., Pangburn, M. K., Janssen, B. J. C., Gros, P., and Vogel, C.-W. (2008). Functional characterization of human C3/cobrar venom factor hybrid proteins for therapeutic complement depletion. Dev Comp Immunol, in press
15. Fujita, T., Matsushita, M., and Endo, Y. (2004). The lectin-complement pathway - its role in innate immunity and evolution. Immunol Rev 198, 185-202
16. Gowda, D. C., Schultz, M., Bredehorst, R., and Vogel, C.-W. (1992). Structure of the major oligosaccharide of cobra venom factor. Mol Immunol 29, 335-342
17. Gowda, D. C., Petrella, E. C., Raj, T. T., Bredehorst, R., and Vogel, C.-W. (1994). Immunoreactivity and function of oligosaccharides in cobra venom factor. J Immunol 152, 2977-2986
18. Gowda, D. C., Glushka, J., Halbeek, H., Thotakura, R. N., Bredehorst, R., and Vogel, C.-W. (2001). N-linked oligosaccharides of cobra venom factor contain novel alpha(1-3)galactosylated Le(x) structures. Glycobiology 11, 195-208
19. Grier, A. H., Schultz, M., and Vogel, C.-W. (1987). Cobra venom factor and human C3 share carbohydrate antigenic determinants. J Immunol 139, 1245-1252
20. Guo, R. F. and Ward, P. A. (2005). Role of C5a in inflammatory responses. Annu Rev Immunol 23, 821-852
21. Hebell, T., Ahearn, J. M., and Fearon, D. T. (1991). Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 254, 102-105
22. Hew, B. E., Thorne, M., Fritzinger, D. C., and Vogel, C.-W. (2004). Humanized cobra venom factor (CVF): Generation of Human C3 derivitives with CVF-like function. Mol Immunol 41, 244-245
23. Hillmen, P., Hall, C., Marsh, J. C., Elebute, M., Bombara, M. P., Petro, B. E., Cullen, M. J., Richards, S. J., Rollins, S. A., Mojcik, C. F., and Rother, R. P. (2004). Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350, 552-559
24. Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J., Honig, B., Shaw, D. E., and Friesner, R. A. (2004). A hierarchical approach to all-atom protein loop prediction. Proteins 55, 351-367
25. Janssen, B. J., Huizinga, E. G., Raaijmakers, H. C., Roos, A., Daha, M. R., Nilsson-Ekdahl, K., Nilsson, B., and Gros, P. (2005). Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437, 505-511
26. Janssen, B. J., Christodoulidou, A., McCarthy, A., Lambris, J. D., and Gros, P. (2006). Structure of C3b reveals conformational changes that underlie complement activity. Nature 444, 213-216
27. KÖ;ck, M. A., Hew, B. E., Bammert, H., Fritzinger, D. C., and Vogel, C. W. (2004). Structure and function of recombinant cobra venom factor. J Biol Chem 279, 30836-30843
28. Kölln, J., Spillner, E., Andrä, J., Klensang, K., and Bredehorst, R. (2004a). Human C3 derivatives engineered for decomplementation by forming stable C3 convertases. Mol Immunol 41, 259
29. Kölln, J., Spillner, E., Andr̈, J., Klensang, K., and Bredehorst, R. (2004b). Complement inactivation by recombinant human C3 derivatives. J Immunol 173, 5540-5545
30. Kölln, J., Bredehorst, R., and Spillner, E. (2005). Engineering of human complement component C3 for catalytic inhibition of complement. Immunol Lett 98, 49-56
31. Lachmann, P. J. and Halbwachs, L. (1975). The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol 21, 109-114
32. Maillard, J. L., and Zarco, R. M. (1968). [Decomplementization by a factor extracted from cobra venom. Effect on several immune reactions of the guinea pig and rat]. Ann Inst Pasteur (Paris) 114, 756-774
33. Medicus, R. G., Götze, O., and Müller-Eberhard, H. J. (1976). The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol 5, 1049-1055
34. Mollnes, T. E. and Kirschfink, M. (2006). Strategies of therapeutic complement inhibition. Mol Immunol 43, 107-121
35. Morgan, B. P. and Harris, C. L. (2003). Complement therapeutics; history and current progress. Mol Immunol 40, 159-170
36. Nagaki, K., Iida, K., Okubo, M., and Inai, S. (1978). Reaction mechanisms of beta1H globulin. Int Arch Allergy Appl Immunol 57, 221-232
37. Nelson, R. A., Jr. (1966). A new concept of immunosuppression in hypersensitivity reactions and in transplantation immunity. Surv Ophthalmol 11, 498-505
38. Pangburn, M. K., Schreiber, R. D., and Müller-Eberhard, H. J. (1977). Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med 146, 257-270
39. Pangburn, M. K. and Müller-Eberhard, H. J. (1986). The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J 235, 723-730
40. Sahu, A. and Lambris, J. D. (2000). Complement inhibitors: a resurgent concept in antiinflammatory therapeutics. Immunopharmacology 49, 133-148
41. Shernan, S. K., Fitch, J. C., Nussmeier, N. A., Chen, J. C., Rollins, S. A., Mojcik, C. F., Malloy, K. J., Todaro, T. G., Filloon, T., Boyce, S. W., Gangahar, D. M., Goldberg, M., Saidman, L. J., and Mangano, D. T. (2004). Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 77, 942-949; discussion 949-950
42. Till, G. O., Johnson, K. J., Kunkel, R., and Ward, P. A. (1982). Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest 69, 1126-1135
43. Till, G. O., Morganroth, M. L., Kunkel, R., and Ward, P. A. (1987). Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat. Am J Pathol 129, 44-53
44. Vogel, C.-W. (1991). Cobra venom factor, the complement-activating protein of cobra venom. In: Handbook of Natural Toxins: Reptile and Amphibian Venoms, Vol. 5. Anthony Tu (ed.). Marcel Dekker, New York, pp. 147-188
45. Vogel, C.-W., and Müller-Eberhard, H. J. (1982). The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J Biol Chem 257, 8292-8299
46. Vogel, C.-W., and Müller-Eberhard, H. J. (1984). Cobra venom factor: improved method for purification and biochemical characterization. Journal of Immunology Methods 73, 203-220
47. Vogel, C.-W. and Fritzinger, D. C. (2007). Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion. Curr Pharm Des 13, 2916-2926
48. Vogel, C.-W., Smith, C. A., and Müller-Eberhard, H. J. (1984). Cobra venom factor: structural homology with the third component of human complement. J Immunol 133, 3235-3241
49. Vogel, C.-W., Bredehorst, R., Fritzinger, D. C., Grunwald, T., Ziegelmüller, P., and Kock, M. A. (1996). Structure and function of cobra venom factor, the complement-activating protein in cobra venom. Adv Exp Med Biol 391, 97-114
50. Vogel, C. W., Fritzinger, D. C., Hew, B. E., Thorne, M., and Bammert, H. (2004). Recombinant cobra venom factor. Mol Immunol 41, 191-199
51. Walsh, M. C., Bourcier, T., Takahashi, K., Shi, L., Busche, M. N., Rother, R. P., Solomon, S. D., Ezekowitz, R. A., and Stahl, G. L. (2005). Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 175, 541-546
52. Wehrhahn, D., Meiling, K., Fritzinger, D. C., Bredehorst, R., Andrä, J., and Vogel, C.-W. (2000). Analysis of the structure/function relationship of Cobra Venom Factor (CVF) and C3: generation of CVF/cobraC3 hybrid proteins. Immunopharmacology 49, 94
53. Weisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C., Jr., Carson, G. R., Concino, M. F., oyle, M. P., Roux, K. H., Weisfeldt, M. L., and Fearon, D. T. (1990). Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249, 146-151
54. Whaley, K., and Ruddy, S. (1976). Modulation of the alternative complement pathways by beta1H globulin. J Exp Med 144, 1147-1163
55. Zhou, C. Y., McInnes, E., Copeman, L., Langford, G., Parsons, N., Lancaster, R., Richards, A., Carrington, C., and Thompson, S. (2005). Transgenic pigs expressing human CD59, in combination with human membrane cofactor protein and human decay-accelerating factor. Xenotransplantation 12, 142-148